Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.56 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.56 |
| ▸ | PPARA | Q07869 | 2/20 | 0.55 |
| ▸ | PPARG | P37231 | 1/20 | 0.55 |
| ▸ | MMP13 | P45452 | 1/20 | 0.53 |
| ▸ | BRD4 | O60885 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | FAAH | O00519 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | LTA4H | P09960 | 2/20 | 0.51 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.51 |
| ▸ | AR | P10275 | 1/20 | 0.51 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13140901 | 0.90 | CYSLTR2 (0.55) | MAPK1L3MBTL1TSHRTDP1CYSLTR2 | |
| SCHEMBL8279857 | 0.89 | CYSLTR2 (0.54) | MAPK1L3MBTL1TSHRTDP1CYSLTR2 | |
| Hydrochloric Acid SCHEMBL688914 | 0.88 | CYSLTR2 (0.53) | MAPK1L3MBTL1TSHRTDP1CYSLTR2 | |
| SCHEMBL3159659 | 0.87 | PPARA (0.60) | MAPK1L3MBTL1TSHRTDP1CYSLTR2 | |
| SCHEMBL13141072 | 0.87 | CYSLTR2 (0.55) | MAPK1L3MBTL1TSHRTDP1CYSLTR2 | |
| SCHEMBL3159484 | 0.85 | PPARA (0.59) | MAPK1L3MBTL1TSHRTDP1CYSLTR2 | |
| SCHEMBL4572152 | 0.85 | PPARA (0.59) | MAPK1L3MBTL1TSHRTDP1CYSLTR2 | |
| SCHEMBL10054169 | 0.85 | L3MBTL1 (0.62) | MAPK1L3MBTL1TDP1CYSLTR2CYSLTR1 | |
| SCHEMBL12698684 | 0.84 | ALDH1A1 (0.67) | MAPK1L3MBTL1TSHRTDP1CYSLTR2 | |
| SCHEMBL8955658 | 0.84 | CYSLTR2 (0.63) | MAPK1L3MBTL1TSHRTDP1CYSLTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2445892-A1 | 5-MEMBERED HETEROARYL DERIVATIVES USED AS SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONISTS | Glaxo Group Limited (GB) | 2012-05-02 | — | — | EP | disclosed |
| US-20120101136-A1 | 5-MEMBERED HETEROARYL DERIVATIVES USED AS SPHINGOSINE 1- PHOSPHATE RECEPTOR AGONISTS | GLAXO GROUP LIMITED | 2012-04-26 | — | — | US | disclosed |
| US-20120101136-A1 | 5-MEMBERED HETEROARYL DERIVATIVES USED AS SPHINGOSINE 1- PHOSPHATE RECEPTOR AGONISTS | GLAXO GROUP LIMITED | 2012-04-26 | — | — | US | disclosed |
| US-20120101136-A1 | 5-MEMBERED HETEROARYL DERIVATIVES USED AS SPHINGOSINE 1- PHOSPHATE RECEPTOR AGONISTS | GLAXO GROUP LIMITED | 2012-04-26 | — | — | US | disclosed |
| WO-2010148650-A1 | 5-MEMBERED HETEROARYL DERIVATIVES USED AS SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2010-12-29 | — | — | WO | disclosed |
| WO-2010148650-A1 | 5-MEMBERED HETEROARYL DERIVATIVES USED AS SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2010-12-29 | — | — | WO | disclosed |
| US-20080027094-A1 | Tropane Compounds and Pharmaceutical Compositions Comprising the Same as an Active Ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-01-31 | — | — | US | disclosed |
| US-20080027094-A1 | Tropane Compounds and Pharmaceutical Compositions Comprising the Same as an Active Ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-01-31 | — | — | US | disclosed |
| EP-1785421-A1 | TROPAN COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027094-A1 | Tropane Compounds and Pharmaceutical Compositions Comprising the Same as an Active Ingredient | CHRM1, CHRM3, CHRM2 | MAPK1 2081/4885L3MBTL1 2883/4885TSHR 78/4885 |
| US-20120101136-A1 | 5-MEMBERED HETEROARYL DERIVATIVES USED AS SPHINGOSINE 1- PHOSPHATE RECEPTOR AGONISTS | S1PR1, S1PR5, S1PR3 | MAPK1 1599/4885L3MBTL1 4201/4885TSHR 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.